JPS6147833B2 - - Google Patents
Info
- Publication number
- JPS6147833B2 JPS6147833B2 JP55136175A JP13617580A JPS6147833B2 JP S6147833 B2 JPS6147833 B2 JP S6147833B2 JP 55136175 A JP55136175 A JP 55136175A JP 13617580 A JP13617580 A JP 13617580A JP S6147833 B2 JPS6147833 B2 JP S6147833B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- thiobiuret
- reaction
- general formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 9
- -1 thiobiuret compound Chemical class 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- YCLDXRHGQVDVJR-UHFFFAOYSA-N carbamothioylurea Chemical class NC(=O)NC(N)=S YCLDXRHGQVDVJR-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 6
- 239000012948 isocyanate Substances 0.000 description 5
- 150000002513 isocyanates Chemical class 0.000 description 5
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- MDKCFLQDBWCQCV-UHFFFAOYSA-N benzyl isothiocyanate Chemical compound S=C=NCC1=CC=CC=C1 MDKCFLQDBWCQCV-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 150000002540 isothiocyanates Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000003501 anti-edematous effect Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JAEZSIYNWDWMMN-UHFFFAOYSA-N 1,1,3-trimethylthiourea Chemical compound CNC(=S)N(C)C JAEZSIYNWDWMMN-UHFFFAOYSA-N 0.000 description 2
- COSWCAGTKRUTQV-UHFFFAOYSA-N 1,1,3-trimethylurea Chemical compound CNC(=O)N(C)C COSWCAGTKRUTQV-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- QAADZYUXQLUXFX-UHFFFAOYSA-N N-phenylmethylthioformamide Natural products S=CNCC1=CC=CC=C1 QAADZYUXQLUXFX-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940117953 phenylisothiocyanate Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- NOHQUGRVHSJYMR-UHFFFAOYSA-N 1-chloro-2-isocyanatobenzene Chemical compound ClC1=CC=CC=C1N=C=O NOHQUGRVHSJYMR-UHFFFAOYSA-N 0.000 description 1
- MZZVFXMTZTVUFO-UHFFFAOYSA-N 1-chloro-4-isothiocyanatobenzene Chemical compound ClC1=CC=C(N=C=S)C=C1 MZZVFXMTZTVUFO-UHFFFAOYSA-N 0.000 description 1
- GGYRVEUCCUJDFK-UHFFFAOYSA-N 1-ethyl-1,3-dimethylurea Chemical compound CCN(C)C(=O)NC GGYRVEUCCUJDFK-UHFFFAOYSA-N 0.000 description 1
- SXJYSIBLFGQAND-UHFFFAOYSA-N 1-isocyanato-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(N=C=O)=C1 SXJYSIBLFGQAND-UHFFFAOYSA-N 0.000 description 1
- FMDGXCSMDZMDHZ-UHFFFAOYSA-N 1-isocyanato-4-methoxybenzene Chemical compound COC1=CC=C(N=C=O)C=C1 FMDGXCSMDZMDHZ-UHFFFAOYSA-N 0.000 description 1
- GFEPANUKFYVALF-UHFFFAOYSA-N 1-isothiocyanato-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(N=C=S)=C1 GFEPANUKFYVALF-UHFFFAOYSA-N 0.000 description 1
- VRPQCVLBOZOYCG-UHFFFAOYSA-N 1-isothiocyanato-4-methoxybenzene Chemical compound COC1=CC=C(N=C=S)C=C1 VRPQCVLBOZOYCG-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
本発明は新規な置換チオビウレツト化合物に関
するものである。本発明に係る置換チオビウレツ
ト化合物は一般式
(式中、R1、R2およびR3は低級アルキル基
を、R4はフエニル基、置換基としてハロゲン原
子、低級アルキル基、低級アルコキシ基もしくは
トリフルオルメチル基を有するフエニル基または
アラルキル基を意味し、XおよびYは相異なつて
酸素原子またはイオウ原子を意味する。)で表わ
される。
上記一般式(1)で示される置換チオビウレツト化
合物のR1、R2、R3で表わされる低級アルキル基
およびR4のフエニル基の置換基として表わされ
る低級アルキル基は、炭素数1〜6の鎖状あるい
は分枝状のアルキル基で、例えばメチル、エチ
ル、プロピル、イソプロピル、ブチル、ペンチ
ル、ヘキシル基等を、R4のフエニル基の置換基
の低級アルコキシ基は炭素数1〜5のアルコキシ
基で、例えばメトキシ、エトキシ、プロポキシ、
ブトキシ、ペントキシ基等を、ハロゲン原子とし
ては弗素、塩素、臭素、沃素を、アラルキル基と
してはベンジル、フエネチル基等を挙げることが
できる。
本発明の置換チオビウレツト化合物は、新規化
合物であつて、抗炎症作用、鎮痛作用、抗アレル
ギー作用、利尿作用、抗菌作用および抗けいれん
作用を有し、抗炎症剤あるいは鎮痛剤として有用
な化合物である。
本発明に係る置換チオビウレツト化合物は、例
えば下記の反応式で示されるように一般式(2)で示
される尿素あるいはチオ尿素と一般式(3)で示され
るイソシアナートあるいはイソチオシアナートを
反応させることにより合成される。
(式中、R1、R2、R3、R4、XおよびYは前記
と同一である。)
本反応における一般式(2)で示される尿素あるい
はチオ尿素と一般式(3)で示されるイソシアナート
あるいはイソチオシアナートはいずれも公知化合
物であり、その反応は通常溶媒中あるいは無溶媒
下に行われる。溶媒としては反応に関与しないも
のである限り特に限定されず、一般にエーテル、
ジオキサン、テトラヒドロフラン等のエーテル
類、ベンゼン、トルエン、キシレン等の芳香族炭
化水素類、クロロホルム、ジクロルメタン、ジク
ロルエタン等のハロゲノアルカン類が使用され
る。本反応は無触媒下でも十分進行するが、触媒
としては酸性触媒あるいは塩基性触媒を用いるこ
ともできる。酸性触媒としては、例えば塩化第二
スズ、四塩化チタン、塩化アルミニウム等のルイ
ス酸が使用され、また塩基性触媒としては例えば
水素化ナトリウム、ナトリウムアミド等が使用さ
れる。
一般式(2)で示される尿素あるいはチオ尿素と一
般式(3)で示されるイソシアナートあるいはイソチ
オシアナートおよび触媒の使用割合は適宜選択す
ればよいが、一般に等モル量程度使用するのが有
利である。反応温度も適宜選択すればよいが、一
般に−20℃〜溶媒の還流程度の温度において行な
うと有利に進行する。酸性触媒を用いた反応で
は、反応終了後、チオビウレツトと金属の錯体が
反応溶液中より沈殿してくる。これを取し、水
不混和性溶媒と、水もしくは酸性水溶液の混合液
中で混合させることにより、チオビウレツトが金
属錯体から容易に遊離される。これらは通常の分
離手段、例えば再結晶、カラムクロマトグラフイ
ー等により単離可能である。一般式(1)で示される
置換チオビウレツト誘導体の実施例は下記のとお
りであり、これらの実施例によつて得た化合物を
表1に示す。
実施例 1
5―(3―トリフルオルメチルフエニル)―
1,1,3―トリメチル―4―チオビウレツト
(化合物No.20)の合成
水素化ナトリウム(50%油性)1.44g(0.03モ
ル)を無水テトラヒドロフラン80ml中懸濁撹拌下
10℃以下で、1,1,3―トリメチル尿素3g
(0.03モル)を加え、室温にて終夜撹拌した。反
応液を0℃以下に冷却し、3―トリフルオルメチ
ルフエニルイソチオシアナート6.0g(0.03モ
ル)の無水テトラヒドロフラン10ml溶液を滴下
後、0℃以下で4時間撹拌した。終了後酢酸酸性
とし、水を加えて溶媒を減圧下留去し、エーテル
抽出後芒硝にて乾燥した。エーテルを留去し、残
渣をシリカゲルカラムクロマトグラフイー(溶媒
系;ベンゼン:アセトン=5:1)にて単離後、
エーテルより再結晶して、5―(3―トリフルオ
ルメチルフエニル)―1,1,3―トリメチル―
4―チオビウレツト6.8gを得た。(収率75%)
実施例 2〜6
化合物No.12、14、16、18、22の化合物の合成
1,1,3―トリメチル尿素とイソチオシアナ
ートとして、それぞれフエニルイソチオシアナー
ト、4―クロルフエニルイソチオシアナート、4
―メチルフエニルイソチオシアナート、4―メト
キシフエニルイソチオシアナート、ベンジルイソ
チオシアナートを使用し、実施例1と同様の操作
で合成した。
実施例 7,8
化合物No.23、24の化合物の合成
1―エチル―1,3―ジメチル尿素と、それぞ
れフエニルイソチオシアナート、ベンジルイソチ
オシアナートを使用し、実施例1と同様の操作で
合成した。
実施例 9
5―(4―クロルフエニル)―1,1,3―ト
リメチル―2―チオビウレツト(化合物No.15)
の合成
1,1,3―トリメチルチオ尿素5.9g(0.05
モル)を乾燥ジクロルエタン50mlに溶かし、4―
クロルフエニルイソシアナート7.6g(0.05モ
ル)を加えて、0℃以下に冷却し、無水塩化第二
スズ13g(0.05モル)の乾燥ジクロルエタン10ml
溶液を滴下後、室温で終夜撹拌した。その反応混
合物からの析出物を取し、ジクロルエタンにて
洗浄後、クロロホルム50mlおよび10%塩酸水溶液
40mlと混合撹拌した。有機層を分取し、水洗後芒
硝にて乾燥した。クロロホルムを留去し、残渣を
シリカゲルカラムクロマトグラフイ―(溶媒系;
クロロホルム:エタノール=10:1)にて単離
後、エーテルより再結晶し、5―(4―クロルフ
エニル)―1,1,3―トリメチル―2―チオビ
ウレツト11.2gを得た。(収率83%)
実施例 10〜13
化合物No.13,17,19,21の化合物の合成
1,1,3―トリメチルチオ尿素と、イソシア
ナートとして、それぞれフエニルイソシアナー
ト、4―メチルフエニルイソシアナート、4―メ
トキシフエニルイソシアナート、3―トリフルオ
ルメチルフエニルイソシアナートを使用し、実施
例9と同様の操作で合成した。
次に本発明化合物の抗浮腫作用、鎮痛作用およ
び急性毒性を下記の試験方法により測定したの
で、その結果を表2に示す。
抗浮腫作用
急性カラゲニン浮腫試験法〔目本薬理学雑誌、
56、575(1960)〕に従つて、Wistar系雄性ラツ
ト(体重150〜180g)各群6〜8匹を用い、一夜
絶食後、薬物100mg/Kgまたは200mg/Kgを経口投
与し、その1時間後に起炎物質(1%カラゲニン
液、0.1ml/ラツト)を足蹠皮下に注入し、以後
経時的に足容積を測定した。
抗浮腫作用は、起炎物質注入後3時間目におけ
る浮腫抑制率(%)で示した。
鎮痛作用
1 酢酸ストレツチング法
Kosterらの方法〔Federation Proceedings
18、412(1959)〕に従つて、ddy系雄性マウス
(体重20〜25g)各群6〜8匹を用い、一夜絶食
後、薬物50mg/Kg、100mg/Kgまたは20mg/Kgを
経口投与した1時間後に、0.7%酢酸を動物一匹
あたり0.2mlずつ腹腔内投与し、ストレツチング
症状を観察して抑制率(%)を求めた。
2 ハフナー変法
藤村らの変法〔京都大学化学研究所報告第25
集、36(1951)〕に従つて、ddy系雄性マウス
(体重20〜25g)各群6〜8匹を用い、一夜絶食
後、薬物100mg/Kgまたは200mg/Kgを経口投与し
た45分後に、閾値用量の塩酸モルヒネ(1.5〜2.5
mg/Kg)を皮下注射し、以後1時間のクレンメに
よる疼痛反応を観察し、抑制率(%)を求めた。
急性毒性試験
ddy系雄性マウス(体重20〜25g)を用い、一
夜絶食後、薬物を経口投与した。投与後の一般症
状は7日間観察し、投与量(mg/Kg)に対する死
亡数/一群動物数として表わした。
以上の試験において、薬物はすべて0.25%カル
ボキシメチルセルロース液中に懸濁して用いた。
The present invention relates to novel substituted thiobiuret compounds. The substituted thiobiuret compounds according to the present invention have the general formula (In the formula, R 1 , R 2 and R 3 are lower alkyl groups, R 4 is a phenyl group, and a phenyl group or aralkyl group having a halogen atom, lower alkyl group, lower alkoxy group or trifluoromethyl group as a substituent. and X and Y each independently represent an oxygen atom or a sulfur atom. The lower alkyl group represented by R 1 , R 2 , and R 3 of the substituted thiobiuret compound represented by the above general formula (1) and the lower alkyl group represented as a substituent of the phenyl group of R 4 have 1 to 6 carbon atoms. A chain or branched alkyl group, such as methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl group, etc., and a lower alkoxy group as a substituent of the phenyl group in R 4 is an alkoxy group having 1 to 5 carbon atoms. For example, methoxy, ethoxy, propoxy,
Examples of the halogen atom include fluorine, chlorine, bromine, and iodine, and examples of the aralkyl group include benzyl and phenethyl groups. The substituted thiobiuret compound of the present invention is a novel compound that has anti-inflammatory, analgesic, anti-allergic, diuretic, anti-bacterial and anti-spasmodic effects, and is a compound useful as an anti-inflammatory agent or analgesic. . The substituted thiobiuret compound according to the present invention can be obtained by, for example, reacting urea or thiourea represented by general formula (2) with isocyanate or isothiocyanate represented by general formula (3) as shown in the reaction formula below. is synthesized by (In the formula, R 1 , R 2 , R 3 , R 4 , X and Y are the same as above.) In this reaction, urea or thiourea represented by general formula (2) and The isocyanate or isothiocyanate used is a known compound, and the reaction is usually carried out in a solvent or without a solvent. The solvent is not particularly limited as long as it does not participate in the reaction, and generally includes ether,
Ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, and halogenoalkanes such as chloroform, dichloromethane and dichloroethane are used. Although this reaction proceeds satisfactorily even in the absence of a catalyst, an acidic catalyst or a basic catalyst can also be used as the catalyst. As acidic catalysts, for example, Lewis acids such as stannic chloride, titanium tetrachloride, aluminum chloride, etc. are used, and as basic catalysts, for example, sodium hydride, sodium amide, etc. are used. The ratio of the urea or thiourea represented by the general formula (2), the isocyanate or isothiocyanate represented by the general formula (3), and the catalyst may be selected as appropriate, but it is generally advantageous to use equimolar amounts. It is. Although the reaction temperature may be selected as appropriate, it generally proceeds advantageously when carried out at a temperature of -20°C to about reflux of the solvent. In a reaction using an acidic catalyst, a complex of thiobiuret and metal precipitates from the reaction solution after the reaction is completed. Thiobiuret is easily released from the metal complex by mixing it with a water-immiscible solvent in a mixture of water or an acidic aqueous solution. These can be isolated by conventional separation means such as recrystallization, column chromatography, etc. Examples of substituted thiobiuret derivatives represented by general formula (1) are as follows, and the compounds obtained by these examples are shown in Table 1. Example 1 5-(3-trifluoromethylphenyl)-
Synthesis of 1,1,3-trimethyl-4-thiobiuret (Compound No. 20) 1.44 g (0.03 mol) of sodium hydride (50% oily) was suspended in 80 ml of anhydrous tetrahydrofuran with stirring.
1,1,3-trimethylurea 3g below 10℃
(0.03 mol) was added and stirred at room temperature overnight. The reaction solution was cooled to below 0°C, and a solution of 6.0 g (0.03 mol) of 3-trifluoromethylphenyl isothiocyanate in 10 ml of anhydrous tetrahydrofuran was added dropwise, followed by stirring at below 0°C for 4 hours. After completion of the reaction, the mixture was acidified with acetic acid, water was added, the solvent was distilled off under reduced pressure, and the mixture was extracted with ether and dried over sodium sulfate. After distilling off the ether and isolating the residue using silica gel column chromatography (solvent system: benzene:acetone=5:1),
Recrystallized from ether to give 5-(3-trifluoromethylphenyl)-1,1,3-trimethyl-
6.8 g of 4-thiobiuret was obtained. (Yield 75%) Examples 2 to 6 Synthesis of compounds No. 12, 14, 16, 18, and 22 As 1,1,3-trimethylurea and isothiocyanate, phenylisothiocyanate and 4- Chlorphenyl isothiocyanate, 4
Synthesis was performed in the same manner as in Example 1 using -methylphenylisothiocyanate, 4-methoxyphenylisothiocyanate, and benzylisothiocyanate. Example 7, 8 Synthesis of compounds Nos. 23 and 24 Using 1-ethyl-1,3-dimethylurea and phenylisothiocyanate and benzylisothiocyanate, respectively, in the same manner as in Example 1. Synthesized. Example 9 5-(4-chlorophenyl)-1,1,3-trimethyl-2-thiobiuret (Compound No. 15)
Synthesis of 1,1,3-trimethylthiourea 5.9g (0.05
mol) in 50 ml of dry dichloroethane, 4-
Add 7.6 g (0.05 mol) of chlorphenyl isocyanate, cool to below 0°C, and add 13 g (0.05 mol) of anhydrous stannic chloride to 10 ml of dry dichloroethane.
After the solution was added dropwise, the mixture was stirred at room temperature overnight. Collect the precipitate from the reaction mixture, wash it with dichloroethane, then add 50 ml of chloroform and 10% aqueous hydrochloric acid solution.
40 ml and stirred. The organic layer was separated, washed with water, and dried with sodium sulfate. Chloroform was distilled off, and the residue was subjected to silica gel column chromatography (solvent system;
After isolation with chloroform:ethanol=10:1), recrystallization from ether gave 11.2 g of 5-(4-chlorophenyl)-1,1,3-trimethyl-2-thiobiuret. (Yield 83%) Examples 10 to 13 Synthesis of compounds No. 13, 17, 19, and 21 1,1,3-trimethylthiourea and isocyanates such as phenyl isocyanate and 4-methyl fluoride, respectively. Synthesis was performed in the same manner as in Example 9 using enyl isocyanate, 4-methoxyphenyl isocyanate, and 3-trifluoromethyl phenyl isocyanate. Next, the anti-edema effect, analgesic effect, and acute toxicity of the compound of the present invention were measured by the following test methods, and the results are shown in Table 2. Anti-edema effect Acute carrageenan edema test method [Memoto Pharmacology Journal,
56 , 575 (1960)], 100 mg/Kg or 200 mg/Kg of the drug was orally administered to 6 to 8 male Wistar rats (body weight 150 to 180 g) in each group after an overnight fast, and the drug was administered orally for 1 hour. Afterwards, a inflammatory substance (1% carrageenan solution, 0.1 ml/rat) was subcutaneously injected into the footpad, and the foot volume was measured over time. The anti-edema effect was expressed as the edema suppression rate (%) 3 hours after injection of the inflammatory substance. Analgesic effect 1 Acetic acid stretching method Koster et al.'s method [Federation Proceedings
18 , 412 (1959)], 6 to 8 male DDY mice (body weight 20 to 25 g) were used in each group, and after an overnight fast, 50 mg/Kg, 100 mg/Kg, or 20 mg/Kg of the drug was orally administered. One hour later, 0.2 ml of 0.7% acetic acid was intraperitoneally administered to each animal, and the stretching symptoms were observed to determine the inhibition rate (%). 2 Modified Hafner method Modified method of Fujimura et al. [Kyoto University Chemical Research Institute Report No. 25]
36 (1951)], using 6 to 8 male DDY mice (body weight 20 to 25 g) in each group, after an overnight fast, 45 minutes after oral administration of 100 mg/Kg or 200 mg/Kg of the drug. Threshold dose of morphine hydrochloride (1.5-2.5
mg/Kg) was injected subcutaneously, and the pain response due to the cream was observed for 1 hour thereafter to determine the suppression rate (%). Acute Toxicity Test The drug was orally administered to male DDY mice (body weight 20-25 g) after an overnight fast. General symptoms after administration were observed for 7 days and expressed as the number of deaths/number of animals per group relative to the dose (mg/Kg). In the above tests, all drugs were suspended in 0.25% carboxymethyl cellulose solution.
【表】【table】
【表】【table】
Claims (1)
を、R4はフエニル基、置換基としてハロゲン原
子、低級アルキル基、低級アルコキシ基もしくは
トリフルオルメチル基を有するフエニル基または
アラルキル基を意味し、XおよびYは相異なつて
酸素原子またはイオウ原子を意味する。)で表わ
される置換チオビウレツト化合物。[Claims] 1. General formula (In the formula, R 1 , R 2 and R 3 are lower alkyl groups, R 4 is a phenyl group, and a phenyl group or aralkyl group having a halogen atom, lower alkyl group, lower alkoxy group or trifluoromethyl group as a substituent. and X and Y each independently represent an oxygen atom or a sulfur atom).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13617580A JPS5759857A (en) | 1980-09-29 | 1980-09-29 | Subsituted thiobiuret compound |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13617580A JPS5759857A (en) | 1980-09-29 | 1980-09-29 | Subsituted thiobiuret compound |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5759857A JPS5759857A (en) | 1982-04-10 |
JPS6147833B2 true JPS6147833B2 (en) | 1986-10-21 |
Family
ID=15169073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP13617580A Granted JPS5759857A (en) | 1980-09-29 | 1980-09-29 | Subsituted thiobiuret compound |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5759857A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0649768B2 (en) * | 1985-06-06 | 1994-06-29 | 信越化学工業株式会社 | Method for producing aqueous gel |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5018419A (en) * | 1973-05-10 | 1975-02-26 | ||
JPS53127436A (en) * | 1977-04-12 | 1978-11-07 | Kumiai Chem Ind Co Ltd | 1-(n,n-dialkycarbamoyl)-3-(substd, phenyl) thio-ureas and insecticides containing the same |
-
1980
- 1980-09-29 JP JP13617580A patent/JPS5759857A/en active Granted
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5018419A (en) * | 1973-05-10 | 1975-02-26 | ||
JPS53127436A (en) * | 1977-04-12 | 1978-11-07 | Kumiai Chem Ind Co Ltd | 1-(n,n-dialkycarbamoyl)-3-(substd, phenyl) thio-ureas and insecticides containing the same |
Also Published As
Publication number | Publication date |
---|---|
JPS5759857A (en) | 1982-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4174397A (en) | Thiazolidine derivatives | |
EP0053407B1 (en) | New imidazolylphenyl amidines, processes for their preparation and their pharmaceutical use, and intermediates of preparation | |
JPH026354B2 (en) | ||
KR850000216B1 (en) | Process for preparing piperazine derivatives | |
JP2707936B2 (en) | β-oxo-β-benzenepropanethioamide derivative | |
JPS58219161A (en) | Novel derivatives of 1,3-dihydro-4-(1-hydroxy-2- aminoethyl)-2h-indol-2-one, salts thereof, manufacture, use as drug and composition | |
KR900006118B1 (en) | Process for preparing 4-quinolone derivatives | |
US3957772A (en) | Process for the preparation of 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazine 1,1-dioxide | |
JPH02178263A (en) | Azaazulene derivative, production thereof and anti-allergic and anti-inflammatory containing the derivative as active component | |
JPS6147833B2 (en) | ||
JPS59512B2 (en) | Pyrazole -5- Onkagobutsuno Seizouhouhou | |
Schnur et al. | Improved glucose tolerance in rats treated with oxazolidinediones | |
EP0326108A1 (en) | Antiarthritic isoxazole-4-carboxamides | |
JPH0578554B2 (en) | ||
JPS6223747B2 (en) | ||
US3676463A (en) | Oxobenzofuran carboxamides | |
JPS646193B2 (en) | ||
EP0090275A2 (en) | Isoxazole (5,4-b) pyridines | |
JPH0495071A (en) | Carbamic acid derivative | |
EP0058009A1 (en) | Novel benzanilide derivatives and pharmaceutical compositions containing them | |
JP2658198B2 (en) | Pyranobenzotriazole derivatives | |
JP2579116B2 (en) | Novel 4-methyl-1,3-oxazole compounds, their preparation and pharmaceutical compositions containing them | |
JPH02286663A (en) | Azole-1-alkanamides and their production | |
JPH03173876A (en) | New diphenylthiazole derivative | |
JPH0680041B2 (en) | 2-Pyridylacetic acid derivative, method for producing the same, and medicament containing the same |